{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"23","value":"18.2"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"23","value":"10.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"DoR is defined as the time from first response (stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR)) to the earlier date of progressive disease or death due to any cause.\n\nsCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow aspirates; VGPR=serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level plus urine M-protein level \\< 100 mg/24 h; PR=≥ 50% reduction of serum M protein plus reduction in 24-hour urinary M-protein by ≥ 90% or to \\< 200 mg/24 h.\n\nProgressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.","dispersionType":"Full Range","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG001","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"MEDIAN","populationDescription":"All participants with sCR, CR, VGPR, or PR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a","reportingStatus":"POSTED","timeFrame":"From first response to the date of progression or death due to any cause, whichever occurs first (Up to approixmately 61 months)","title":"Duration of Response (DoR) in Phase 2 and 2a","type":"SECONDARY","unitOfMeasure":"Months"}